Company

News Releases

BioPharmX to Present Phase 2b Clinical Trial Acne Data at Alabama Dermatology Society Summer Symposium

BPX-01 2% formulation reduced inflammatory lesions by 59%

25% of subjects achieved two-grade IGA reduction (to clear/almost clear)

86% of subjects said they would use BPX-01 again

Presentation to be held Friday at 10 a.m. CDT

Jun 22, 2017

MENLO PARK, Calif., June 22, 2017 /PRNewswire/-- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology, will present results of its phase 2b of BPX-01, a unique topical hydrophilic gel formulation of minocycline, at the Alabama Dermatology Society's Summer Symposium being held June 22-25 in Sandestin, Fla.

 (PRNewsfoto/BioPharmX Corporation)

Findings from the phase 2b will be discussed during the presentation "Acne Vulgaris: What Do Available and Newer Therapies Bring to the Table?"  by Dr. James Q. Del Rosso, founder of JDR Dermatology Research, Las Vegas. His presentation is scheduled for 10 a.m. Friday.

The company's poster presentation, entitled "Results from a Randomized, Double-Blind, Vehicle-Control Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate-to-Severe Inflammatory Acne Vulgaris," will take place at 7:00 p.m. CDT today.

Phase 2b data showed the 2% formulation of BPX-01 reduced acne lesions in subjects by 59% (compared to 44% for vehicle) and delivered at least a two-grade reduction in investigator global assessment (IGA) and clear to almost clear for 25% of subjects.  The Phase 2b research was not powered to measure IGA statistical significance.  The study found BPX-01 was generally well tolerated, without any serious drug-related adverse events experienced, no photosensitivity, staining or skin discoloration.

While BioPharmX previously presented phase 2b data to the investor community, the Symposium will be the first time it shares the research in a medical conference. It will also be the first time the medical community hears research showing that subjects had a positive experience with BPX-01.  A survey of subjects at week 12 found that 79% thought BPX-01 2% was easy to use and apply.  86% said they would use BPX-01 2% again.

"Efficacy and safety are crucial to dermatologists and their acne patients, but just as important is patient compliance," said G. Scott Herron, M.D., Ph.D., BioPharmX Medical Director, board-certified dermatologist and fellow of the American Academy of Dermatology.  "Medicines that are easy to use improve compliance.  Phase 2b subjects told us BPX-01 is easy to use and they expressed a willingness to use it again. We believe this gives BPX-01 a significant advantage over topical therapies that have irritating side effects like rashes, dryness or itching, or oral therapies that are associated with headaches, dizziness or diarrhea."

BPX-01 is the first topical gel formulation of minocycline that can penetrate the skin to deliver the antibiotic to the pilosebaceous unit, where acne develops. It is also the first and only stable hydrophilic and non-oil-based topical gel with fully solubilized minocycline. The company's studies are designed to confirm whether BPX-01 will effectively treat acne with lower dosages of the antibiotic with no or fewer adverse side effects.

The American Academy of Dermatology calls acne the "most common skin condition in the United States," affecting up to 50 million Americans. The disease can cause permanent scarring, low self-esteem, depression and anxiety.

About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.

Forward-Looking Statements
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding the safety and medical effects of BPX-01, the effect BPX-01 may have on the treatment of acne, the commencement and results of future trials of BPX-01 and the size of such trials, continued and consistent results in future tests of BPX-01 and absence of side effects of future use of BPX-01. These forward-looking statements may be identified by words such as "plan," "expect," "anticipate," "believe" or similar expressions that are intended to identify such forward-looking statements.

These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the period ended Jan. 31, 2017 and our quarterly report on Form 10-Q for the period ended April 30, 2017. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof, and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

BioPharmX is a registered trademark of BioPharmX, Inc.

 

SOURCE BioPharmX Corporation

For further information: Nina Brauer, nbrauer@biopharmx.com (650) 889-5030 or Jim Martinez, jim@rightstorygroup.com (312) 543-9026


print email rss